

Sélection des publications 2017

- Baltus C, Jorda R, Marot C, Berka K, Bazgier V, Krystof V, Prié G, Viaud-Massuard M.C.
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/cyclin E inhibitors.
Eur. J. of Med. Chem. 2016, 108, 701-719.
- Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.
Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
Leuk Res. 2017, 60 : 94-102
- Aparicio T, Bouché O, Taieb J, Maillard E, Kirscher S, Etienne PL, Faroux R, Khemissa FA, El Hajbi F, Locher C, Rinaldi Y, Lecomte T, Lavau-Denes S, Baconnier M, Oden-Gangloff A, Genet D, Paillaud E, Retornaz F, François E, Bedenne L; PRODIGE 20 investigators.
Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results.
Ann Oncol. 2017 Sep 28. doi: 10.1093/annonc/mdx529. [Epub ahead of print]
- Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, Paintaud G, Heuzé-Vourc'h N, Watier H, Gouilleux-Gruart V.
Crucial role of immune complexes but not FcRn for immunization against anti-TNF-alpha antibodies after a single injection in mice.
J Immunol. 2017, 199 : 418-424
- Ayoub MA, Crépieux P, Koglin M, Parmentier M, Pin JP, Poupon A, Reiter E, Smit M, Steyaert J, Watier H, Wilkinson T.
Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.
MAbs. 2017, 9 : 735-741
- Bejan-Angoulvant T, Ternant D, Daoued F, Medina F, Bernard L, Paintaud G, Mulleman D.
Brief report: Relationship between infliximab serum concentrations and risk of infections in patients treated for inflammatory arthritis.
Ann Rheum Dis. 2017, 69 : 108-113.
- Bodier-Montagutelli E, Respaud R, Watier H, Guillon-Munos A.
MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
MAbs. 2017, 9: 579-585
- Boisdrion-Celle M, Metges JP, Capitain O, Adenis A, Raoul JL, Lecomte T, Lam YH, Faroux R, Masliah C, Poirier AL, Berger V, Morel A, Gamelin E.
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Semin Oncol. 2017, 44:24-33.
- Bourgeois J, Ishac N, Medrzycki M, Brachet-Botineau M, Desbourdes L, Gouilleux-Gruart V, Pecnard E, Rouleux-Bonnin F, Gyan E, Domenech J, Mazurier F, Moriggl R, Bunting KD, Herault O, Gouilleux F.
Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Oncotarget. 2017, 8 : 41876-41889

- Caldano M, Raoul W, Rispens T, Bertolotto A.
Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis with Biological Agents.
Ther Drug Monit. 2017, 39 : 350-355
 - Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hichri Y, Guillerm G, Bouscary D, Larosa F, Ojeda-Urbe M, Bernard M, Béné MC, Ifrah N, Cahn JY.
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.
Eur J Haematol. 2017, 98 : 443-449
 - Cartron G, Watier H.
Obinutuzumab: what is there to learn from clinical trials?
Blood 2017, 130 : 581-589
 - Chaigne B, Watier H.
Theranostic of biopharmaceuticals.
Pharmacology & Therapeutics 2017, 175 : 67-74
 - Cheloni G, Tanturli M, Tusa I, Ho DeSouza N, Shan Y, Gozzini A, Mazurier F, Rovida E, Li S, Dello Sbarba P.
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Blood. 2017, 130 : 655-665.
 - Darrouzain F, Bian S, Desvignes C, Bris C, Watier H, Paintaud G, De Vries A.
Immunoassays for measuring serum concentrations of monoclonal antibodies and antibiopharmaceutical antibodies in patients.
Therapeutic Drug Monitoring. 2017, 39 : 316-321
 - Desbourdes L, Javary J, Charbonnier T, Ishac N, Bourgeois J, Iltis A, Chomel JC, Turhan A, Guilloton F, Tarte K, Demattei MV, Ducrocq E, Rouleux-Bonnin F, Gyan E, Herault O, Domenech J.
Alteration analysis of bone marrow mesenchymal stromal cells from de novo acute myeloid leukemia patients at diagnosis.
Stem Cell Dev. 2017, 26 : 709-722
 - Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.
Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017.
 - Dumet C, Pottier J, Gouilleux-Gruart V, Watier H.
Les nouveaux formats structuraux des anticorps thérapeutiques en rhumatologie.
Revue du Rhumatisme 2017
- Dumet C, Pottier J, Gouilleux V, Watier H.
New structural formats of therapeutic antibodies in rheumatology.
Joint Bone Spine 2017 Apr 28. pii: S1297-319X(17)30084-2. doi: 10.1016/j.jbspin.2017.04.007. [Epub ahead of print]
- Fogli A, Demattei MV, Corset L, Vaurs-Barrière C, Chautard E, Biau J, Kémény JL, Godfraind C, Pereira B, Khalil T, Grandin N, Arnaud P, Charbonneau M, Verrelle P.
Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
J Neurooncol. 2017, 135 : 381-390

- Freund P, Kerenyi M, Hager M, Wagner T, Wingelhofer B, Thanh Pham HT, Elabd M, Han X, Valent P, Gouilleux F, Sexl V, Krämer O, Groner B, Moriggl R.
O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.
Leukemia. 2017, 31 : 2132-2142
- Gagez AL, Duroux-Richard I, Leprêtre S, Orsini-Piocelle F, Letestu R, De Guibert S, Tuillon E, Leblond V, Khalifa O, Gouilleux-Gruart V, Banos A, Tournilhac O, Dupuis J, Jorgensen C, Cartron G, Apparailly F.
miR-125b and miR-532-3p predict efficiency of the rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A FILO study.
Haematologica. 2017, 102 : 746-754
- Ghanem S, Friedbichler K, Boudot C, Bourgeois J, Gouilleux-Gruart V, Regnier V, Herault O, Moriggl R, Gouilleux F.
STAT5A/5B-specific expansion and transformation of hematopoietic stem cells.
Blood Cancer J 2017, e514
- Gils A, Bertolotto A, Mulleman D, Bejan-Angoulvant T, Declerck PJ.
Biopharmaceuticals: reference products and biosimilars to treat inflammatory diseases.
Ther Drug Monit. 2017, 39 : 308-315
- Guarino C, Hamon, Y, Croix C, Lamort A-S, Dalley-Choisy S, Marchand-Adam S, Lesner A, Baranek T, Viaud-Massuard M-C, Lauritzen C, Pedersen J, Si-Tahar M, Heuzé-Vourc'h N, Firatli E, Jenne D, Gauthier F, Horwitz M, Borregaard N, Korkmaz B.
Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine protease.
Biochemical Pharmacology 2017, 131 : 52-67
- Ibrahim S, Girault A, Ohresser M, Lereclus E, Paintaud G, Lecomte T, Raoul W.
Monoclonal Antibodies Targeting the IL-17/IL-17RA Axis: An Opportunity to Improve the Efficiency of Anti-VEGF Therapy in Fighting Metastatic Colorectal Cancer?
Clin Colorectal Cancer. 2017 Oct 28. pii: S1533-0028(17)30141-X
- Joubert N, Denevault-Sabourin C, Bryden F, Viaud-Massuard MC.
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Eur J Med Chem. 2017 Aug 23. pii: S0223-5234(17)30660-8. doi: 10.1016/j.ejmech.2017.08.049. [Epub ahead of print]
- Juen L, Brachet-Botineau M, Parmenon C, Bourgeois J, Hérault O, Gouilleux F, Viaud-Massuard MC, Prié G.
New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.
J Med Chem. 2017,60 : 6119-6136
- Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J.
5B9, a monoclonal anti-platelet factor 4 /heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
J Thromb Haemost. 2017 Aug 3. doi: 10.1111/jth.13786. [Epub ahead of print]
- Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibia J, Gottenberg JE.

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

Autoimmun Rev. 2017, 16 : 650-657

- Kraeber-Bodere F, Pallardy A, Maisonneuve H, Champion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol. 2017, 4 : e35-e45

- Lajoie L, Congy-Jolivet N, Bolzec A, Thibault G.

Gradual Increase of FcγRIIIa/CD16a Expression and Shift toward IFN-γ Secretion during Differentiation of CD56dim Natural Killer Cells.

Front Immunol. 2017 Nov 20;8:1556. doi: 10.3389/fimmu.2017.01556. eCollection 2017.

- Le Balc'h E, Grandin N, Demattei MV, Guyétant S, Tallet A, Pagès JC, Ouaiissi M, Lecomte T, Charbonneau M.

Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.

Int J Mol Sci. 2017 Aug 29;18(9)

- Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W.

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.

BMC cancer. 2017, 17:220

- Lévi F, Karaboué A, Etienne-Grimaldi MC, Paintaud G, Focan C, Innominato P, Bouchahda M, Milano G, Chatelut E.

Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.

Clin Pharmacokinet. 2017, 56 :165-177

- Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyétant S, Bieche I, Berger F, de Koning L.

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Br J Cancer. 2017, 117 : 1819-1827

- Lioger B, Edupuganti SR, Mulleman D, Passot C, Desvignes C, Bejan-Angoulvant T, Thibault G, Gouilleux-Gruart V, Mélet J, Paintaud G, Ternant D.

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients.

BJCP. 2017,83 : 1773-1781

- Martin C, Kizlik-Masson C, Pèlerin A, Watier H, Viaud-Massuard MC, Joubert N.

Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

MAbs. 2017 Dec 14:0. doi: 10.1080/19420862.2017.1412130. [Epub ahead of print]

- Medina F, Placencia C, Goupille P, Paintaud G, Balsa A, Mulleman D.

Current practice of therapeutic drug monitoring of biopharmaceuticals in spondyloarthritis.

Ther Drug Monit. 2017, 39 : 364-369

- Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D.
Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
Ther Drug Monit. 2017, 39 : 370-378
- (Goupille P) Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Lancet. 2017, 389 : 2317-2327
- Paintaud G, Passot C, Ternant D, Antonio B, Bejan-Angoulvant T, Pascual-Salcedo D, Mulleman D.
Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.
Ther Drug Monit. 2017, 39 : 339-343
- Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A.
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24.
- Passot C, Pouw M, Mulleman D, Bejan-Angoulvant T, Paintaud G, Dreesen E, Ternant D.
Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
Ther Drug Monit. 2017, 39 : 322-326
- Passot C, Desvignes C, Ternant D, Bejan-Angoulvant T, Duveau AC, Gatault P, Paintaud G.
Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum.
Bioanalysis. 2017, 9 : 1227-1235
- Pottier J, Chastang R, Dumet C, Watier H.
Rethinking the INN system for therapeutic antibodies.
MAbs 2017, 9 : 5-11
- Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsén R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
Leukemia. 2017, 31 : 2326-2335
- Ternant D, Passot C, Aubourg A, Goupille P, Desvignes C, Picon L, Lecomte T, Mulleman D, Paintaud G.
Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration.
Clin Pharmacokinet. 2017 Dec 13. doi: 10.1007/s40262-017-0621-6. [Epub ahead of print]
- Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D.
Influence of FCGR3A-158V/F genotype and CD20 antigen count on target-mediated elimination of rituximab in patients with chronic lymphocytic leukemia. A study of FILO group.
Clin Pharmacokinet. 2017, 56 : 635-647

- Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G.

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a LYSA study.

Blood. 2017, 129 : 2616-2623

- Vayne C, Guery EA, Kizlik-Masson C, Rollin J, Bauters A, Gruel Y, Pouplard C

Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies.

Br J Haematol. 2017, 179 : 811-819

- Veyrat-Durebex C, Debeissat C, Blasco H, Patin F, Henique H, Emond P, Antar C, Gissot V, Herault O, Maillot F.

Hyperphenylalaninemia Correlated with Global Decrease of Antioxidant Genes Expression in White Blood Cells of Adult Patients with Phenylketonuria.

JIMD Rep. 2017 Mar 15. doi: 10.1007/8904_2017_16. [Epub ahead of print]

- Watier H.

[Find your way in the jungle of mAbs].

[Article in French]

Transfus Clin Biol. 2017 Jun 12. pii: S1246-7820(17)30070-8[Epub ahead of print]